Psilocybin is under clinical development by Filament Health and currently in Phase II for Treatment Resistant Depression. According to GlobalData, Phase II drugs for Treatment Resistant Depression have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Psilocybin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Psilocybin overview

Psilocybin (PEX010) is under development for the treatment of major depressive disorder, methamphetamine use disorder, refractory anorexia nervosa, alcohol use disorder, cancer-related anxiety, depression, opium dependence, treatment resistant depression, mild cognitive impairment, chronic pain, substance use disorders including opioid use disorder (OUD), treatment-resistant obsessive-compulsive disorder (TR-OCD) and treatment-resistant post-traumatic stress disorder (TR-PTSD) and eating disorders. It is administered through oral route in the form of capsule. The drug candidate is a tryptamine alkaloid psychedelic which acts by targeting 5-hydroxytryptamine receptor 1A (5HT1A) and 5-hydroxytryptamine receptor 2A (HTR2A) receptors.

Filament Health overview

Filament Health is a natural psychedelic drug development company that discovery and develops natural psychedelic medicines. Filament Health is headquartered in Vancouver, British Columbia, Canada.

For a complete picture of Psilocybin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.